Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

27/11/2018Change of Director's Interests Notice-Dr John CullityDownload
27/11/2018Managing Director's AGM PresentationDownload
27/11/2018Change of Director's Interests Notice-Dr William GarnerDownload
27/11/2018Chairman's AGM AddressDownload
27/11/2018Results of Annual General MeetingDownload
13/11/2018Replacement-Change in substantial holding noticeDownload
12/11/2018Change in substantial holdingDownload
12/11/2018Change of Director's Interest Notice-Dr William GarnerDownload
01/11/2018Response to ASX Price QueryDownload
01/11/2018Race appoints Biosynergy to pursue Bisantrene licensingDownload
1  2  3  4  5  6  7  8  9  10  11  12  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier